Market Performance - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 0.5% at midday, while the Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.3%. The CSI Biotechnology Theme Index and the CSI 300 Pharmaceutical and Health Index both saw a 0.1% increase, whereas the CSI Innovative Drug Industry Index declined by 0.2% [1]. Company Developments - Recently, CloudTop New Medicine announced that the U.S. FDA has approved its cardiovascular product, Lurepirdine injection, for lowering low-density lipoprotein cholesterol levels in patients with hypercholesterolemia. The company plans to submit a listing application in the Greater China region in the first half of 2026, which is expected to boost market confidence in the internationalization prospects of innovative drugs [1].

Core Insights - The company, CloudTop New Horizon, has established a solid foundation over the past eight years through license-in strategies and aims to become a leading global biopharmaceutical company by 2030 with a revenue target of over 15 billion RMB and more than 20 commercialized products [1][2][10] Group 1: Strategic Development - The 2030 development strategy focuses on a dual approach of business development (BD) cooperation and independent research and development, targeting a revenue of over 15 billion RMB and over 20 commercialized products by 2030 [1][2][10] - The company plans to introduce 3-5 late-stage blockbuster products annually over the next five years, enhancing its product pipeline [3][10] - The strategic partnerships with Haisen Biopharmaceuticals will provide commercialization services for six approved products, generating service fees based on quarterly net sales [3][4] Group 2: Product Pipeline and Market Focus - The company will focus on key therapeutic areas such as nephrology, autoimmune diseases, critical care, cardiovascular, and ophthalmology, aiming to create a high-value product portfolio by 2030 [2][10] - The revenue from existing pipelines is projected to be around 9 billion RMB, with new pipeline sales expected to contribute approximately 6 billion RMB [2] - The company has successfully commercialized the drug Nefukang, which has rapidly gained market traction, demonstrating its commercial capabilities [7][10] Group 3: Research and Development - CloudTop New Horizon is advancing its self-developed mRNA platforms, including CAR-T and tumor vaccine platforms, with ongoing clinical trials [8][9] - The company plans to expand its R&D capabilities by introducing and incubating potential platforms, aiming to strengthen its core therapeutic areas [9][10] - The new reversible BTK inhibitor EVER001 has shown promising clinical data, indicating a steady global R&D progress [9] Group 4: Commercialization Strategy - The company is leveraging its integrated commercialization platform, which combines scientific and market insights, to enhance its operational efficiency and productivity [4][8] - The collaboration with Haisen Biopharmaceuticals exemplifies the company's ability to extend its commercialization capabilities to mature products [8] - The company aims to transition from a biotech firm to a comprehensive biopharmaceutical company with global competitiveness, reflecting a broader trend in the Chinese innovative drug industry [8][10]

Group 1 - The stock of CloudTop New Horizon (01952.HK) increased by over 3%, specifically rising by 3.46% to reach HKD 48.44 [2] - The trading volume for CloudTop New Horizon was HKD 131 million at the time of reporting [2]

Group 1 - The core viewpoint of the news is that Genting New Year (01952) has seen a stock increase of over 3% following the FDA approval of its cardiovascular product, LEROCHOLTM (lerodalcibep-liga), for lowering LDL-C levels in adults with high cholesterol [1] - Genting New Year reported a stock price of 48.44 HKD with a trading volume of 131 million HKD at the time of the announcement [1] - The FDA approval allows for the use of LEROCHOLTM in conjunction with diet and exercise for patients with heterozygous familial hypercholesterolemia (HeFH) [1] Group 2 - LEROCHOLTM is a novel small-molecule protein-binding third-generation PCSK9 inhibitor designed to help patients achieve and maintain LDL-C control [2] - As the first PCSK9 inhibitor fusion protein, LEROCHOLTM has low immunogenicity and outstanding safety [2] - The product is developed for patient convenience, allowing for self-administration with a single subcutaneous injection once a month, and has a long room temperature stability of up to 3 months [2]

Core Viewpoint - CloudTop New Horizon (01952) shares rose over 3% following FDA approval of its cardiovascular product LEROCHOLTM (lerodalcibep-liga) for lowering LDL-C levels in adults with high cholesterol [1][2] Group 1: Company Developments - The FDA approved the biologics license application (BLA) for LEROCHOLTM, which is intended for use alongside diet and exercise to reduce LDL-C levels in patients with high cholesterol, including heterozygous familial hypercholesterolemia (HeFH) [1] - In December 2025, CloudTop New Horizon signed a licensing agreement with Haisan Bio to obtain exclusive rights for the further clinical development, registration, and commercialization of LEROCHOLTM in Greater China [1] Group 2: Product Features - LEROCHOLTM is a novel small-molecule protein-binding third-generation PCSK9 inhibitor designed to help patients achieve and maintain LDL-C control targets [2] - As the first PCSK9 inhibitor fusion protein, LEROCHOLTM has low immunogenicity and outstanding safety [2] - The product is designed for patient convenience, allowing self-administration with a single small-volume subcutaneous injection once a month, and has a long room-temperature stability of up to 3 months, making it easy for patients to store and carry [2]

Group 1: Core Insights - The FDA has approved the biologics license application (BLA) for LEROCHOL TM (lerodalcibep-liga), a cardiovascular product from LIB Therapeutics, which aims to lower LDL-C levels in adults with high cholesterol [1] - Cloudtop New Horizon has secured exclusive rights for the clinical development, registration, and commercialization of LEROCHOL in Greater China through a licensing agreement with Haisan Biotech, with plans to submit a BLA in 2026 [1] - The product is expected to drive growth in the company's cardiovascular business, with potential market entry as early as 2027 [1] Group 2: Product Advantages - LEROCHOL is a third-generation PCSK9 inhibitor with three core advantages: low immunogenicity, convenient self-administration with a monthly injection, and flexible storage for up to three months at room temperature [2] - Clinical trials involving over 2,900 patients have shown that LEROCHOL can reduce LDL-C levels by ≥60% in cardiovascular disease patients and by 59% in HeFH patients [2] - A key registration phase III clinical trial in China has demonstrated significant efficacy and safety, achieving primary and secondary endpoints related to LDL-C reduction and atherosclerotic lipid improvement [2] Group 3: Market Demand and Potential - Cardiovascular diseases are a leading cause of death globally and in China, with elevated LDL-C levels being a critical factor in severe cardiovascular events [3] - There is a significant unmet medical need in China, where approximately 400 million people have dyslipidemia, and only 14% receive lipid-lowering treatment [3] - The PCSK9 inhibitor market in China is projected to reach approximately 3 billion yuan in 2024, with a 95% year-on-year growth, and is expected to expand to around 10 billion yuan by 2030 [3] Group 4: Commercial Strategy - Cloudtop New Horizon has established an integrated system driven by scientific and commercial insights for medical, access, market, and sales collaboration, which has been validated in other therapeutic areas [3] - The company aims to leverage this system to ensure successful commercialization of LEROCHOL in the cardiovascular sector in Greater China [3]

Core Viewpoint - The approval of LEROCHOLTM (lerodalcibep-liga) by the FDA marks a significant advancement for the cardiovascular treatment landscape, particularly for patients with high cholesterol levels, including heterozygous familial hypercholesterolemia (HeFH) [1][2][4]. Group 1: Product Overview - LEROCHOLTM is a third-generation PCSK9 inhibitor designed to help patients achieve and maintain LDL-C control targets, with a low immunogenicity profile and excellent safety [2][3]. - The product allows for self-administration with a single subcutaneous injection once a month, offering convenience and stability for patients [2]. - In global Phase III clinical trials involving over 2,900 patients, LEROCHOLTM demonstrated a sustained LDL-C reduction of ≥60% in cardiovascular disease patients and a 59% reduction in HeFH patients [2][3]. Group 2: Clinical Trial Results - The Phase III clinical trial in China for LEROCHOLTM has shown promising results, achieving primary efficacy endpoints for LDL-C reduction and demonstrating good safety and tolerability compared to placebo [3]. - The ongoing high prevalence of elevated LDL-C levels among cardiovascular disease patients highlights the unmet medical needs in this area, with only about 14% of the 400 million individuals with dyslipidemia in China receiving treatment [3]. Group 3: Market Potential - The PCSK9 inhibitor market in China is projected to grow significantly, with an estimated market size of approximately RMB 3 billion in 2024, reflecting a 95% year-on-year increase [6]. - By 2030, the market is expected to expand to around RMB 10 billion, indicating substantial growth potential for LEROCHOLTM, which benefits from a patent exclusivity period until 2039 [6]. Group 4: Commercialization Strategy - The FDA approval of LEROCHOLTM represents a strategic milestone for the company in the cardiovascular and metabolic field, with plans to submit a BLA in China in the first half of next year [1][5]. - The company has established a comprehensive commercialization system that integrates medical insights, market access, and sales, which has been successfully validated in other therapeutic areas [5].

Core Viewpoint - The FDA has approved the biologics license application (BLA) for LEROCHOL (lerodalcibep-liga), a novel cardiovascular product developed by LIB Therapeutics, which is expected to significantly enhance the long-term growth of the cardiovascular business for Cloudtop New Horizon (1952.HK) in Greater China [1][5]. Group 1: Product Overview - LEROCHOL is a third-generation PCSK9 inhibitor designed to help patients achieve and maintain LDL-C control targets, with a low immunogenic profile and excellent safety [2]. - The product allows for self-administration with a single subcutaneous injection once a month, offering convenience for patients [2]. - In global Phase III clinical trials involving over 2,900 patients, LEROCHOL demonstrated a sustained LDL-C reduction of ≥60% in cardiovascular disease patients and a 59% reduction in HeFH patients [2]. Group 2: Clinical Trial Results - The Phase III clinical trial in China has shown promising results, achieving primary efficacy endpoints for LDL-C reduction and demonstrating good safety and tolerability compared to placebo [3]. - High LDL-C levels are a key risk factor for serious cardiovascular events, and lowering LDL-C can improve patient outcomes [3]. Group 3: Market Potential - The PCSK9 inhibitor market in China is projected to grow rapidly, with a market size of approximately RMB 3 billion in 2024, reflecting a 95% year-on-year increase [6]. - By 2030, the market size is expected to expand to around RMB 10 billion, indicating significant growth potential [6]. - LEROCHOL's unique product advantages and solid clinical data, along with patent protection until 2039, position it well to capture a significant market share in a competitive landscape [6]. Group 4: Commercialization Strategy - Cloudtop New Horizon has established a comprehensive commercialization system, which has been successfully validated in other therapeutic areas, to facilitate the market penetration of LEROCHOL [5]. - The company plans to submit the BLA for LEROCHOL in Greater China in the first half of next year, with potential market entry as early as 2027 [5].

产品管线方面，云顶新耀将聚焦肾科、自身免疫、急重症、心血管及眼科等核心方向，通过引进创新资 产与自主研发并行推进，到2030年形成高价值产品组合，并拓展其他蓝海领域的大单品。到2030年，云 顶新耀计划将商业化产品数量提升至20款以上。 经济观察网12月15日，云顶新耀发布2030年发展战略，公司计划到2030年实现收入规模超过150亿元。 其中现有管线销售收入约90亿元，新引进管线销售收入约60亿元，并探索潜在对外授权(License-out)收 入。 董事会主席吴以芳表示，未来五年，公司将聚焦"BD合作+自研"双轮驱动，依托科学与市场洞察，推动 战略领域形成N+X产品组合，把握蓝海大单品机遇。公司计划通过已经建立的BD能力和康桥生态，每 年引进3-5个中后期重磅产品，依托自身精干高效的商业化团队实现每个产品医保后三年销售达峰。 ...

New IPOs - Guoxia Technology (02655) received a subscription rate of 1890.73 times for its public offering in Hong Kong, with a share price of HKD 20.1 [1] - Easy Health (02661), Hansai Aitai-B (03378), and Nobi Kan (02635) are scheduled for public offerings from December 15 to December 18, with expected listing on December 23 [1] Major Events - Luoyang Molybdenum (03993) plans to acquire three major gold mining assets in Brazil for USD 1.015 billion [1] - Zhongwei New Materials (02579) has been included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect securities list [1] - Botai Carlink (02889) received a first project confirmation notice from a leading domestic new energy vehicle client [1] - Xiehe New Energy (00182) intends to sell 100% equity of Cangzhou Julong for CNY 65.3 million [1] - Fosun Pharma (02196) plans to invest a total of CNY 1.412 billion to gain control of Green Valley Pharmaceutical [1] - Youqu Holdings (02177) intends to spend JPY 2.701 billion to acquire the Japanese consulting pharmacy chain Akahige [1] Financial Data - China Metallurgical Group (01618) signed new contracts worth CNY 958.13 billion in the first 11 months, a decrease of 8.6% year-on-year [1] - Xinhua Insurance (01336) reported a cumulative original insurance premium income of CNY 188.85 billion in the first 11 months, an increase of 16% year-on-year [1] - China Southern Airlines (01055) saw a 10.42% year-on-year increase in passenger turnover in November [1] - China Shenhua (01088) reported coal sales of 389.5 million tons in the first 11 months, a decrease of 7.7% year-on-year [1] - China Eastern Airlines (00670) experienced a 10.35% year-on-year increase in passenger turnover in November [1] - Air China (00753) reported a 10.1% year-on-year increase in passenger turnover in November [1] Share Buybacks - Tencent Holdings (00700) repurchased 1.051 million shares for HKD 636 million on December 15 [2] - Xiaomi Group-W (01810) repurchased 7.2 million shares for HKD 302 million on December 15 [2] - Geely Automobile (00175) repurchased 1.991 million shares for HKD 34.7485 million on December 15 [2] - Kuaishou-W (01024) repurchased 462,000 shares for HKD 29.9304 million on December 15 [2] - Rongchang Bio (09995) plans to repurchase shares worth between CNY 2 million and CNY 4 million [2] - Gendyn New Drug (01952) received over HKD 38 million in share purchases from directors and major shareholders [2]